Merrion seeks strategic investor as Novo Nordisk gives up GIPET option exercise
This article was originally published in Scrip
Executive Summary
Merrion Pharmaceuticals, the Dublin, Ireland-based drug delivery technology company, has warned investors that it will not meet its revenue targets for 2011 after it was informed by Novo Nordisk that it will not be exercising an option covering its GIPET technology deal signed 22 December 2010.